Prevention of Pseudomonas aeruginosa infection in cystic fibrosis patients

International Journal of Medical Microbiology

Volumn 300, Issue 8, 2010, Pages 573-577

  Döring, Gerd ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Antibiotics; Cystic fibrosis; Hygiene; Infection; Prevention; Pseudomonas aeruginosa; Vaccines

Indexed keywords

AERUGEN; ALGINIC ACID; ANTIBIOTIC AGENT; BACTERIAL ANTIGEN; BACTERIUM LIPOPOLYSACCHARIDE; CIPROFLOXACIN; COLISTIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; KEYHOLE LIMPET HEMOCYANIN; PLACEBO; PSEUDOGEN; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS VACCINE; RECOMBINANT VACCINE; TOBRAMYCIN; UNCLASSIFIED DRUG;

ANTIBODY TITER; BACTERIAL COLONIZATION; BACTERIAL FLAGELLUM; CLINICAL TRIAL; CROSS INFECTION; CYSTIC FIBROSIS; DISINFECTION; HUMAN; HYGIENE; IMMUNOGENICITY; INFECTION CONTROL; INFECTION PREVENTION; INFLAMMATION; LUNG FIBROSIS; NONHUMAN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SHORT SURVEY; VACCINATION;

ANTI-BACTERIAL AGENTS; BACTERIAL VACCINES; BRONCHOPNEUMONIA; CYSTIC FIBROSIS; HUMANS; INFECTION CONTROL; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 78549238138     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2010.08.010     Document Type: Short Survey

References (87)

1. Adamo R., Sokol S., Soong G., Gomez M.I., Prince A. Pseudomonas aeruginosa flagella activate airway epithelial cells through asialoGM1 and toll-like receptor 2 as well as toll-like receptor 5. Am. J. Respir. Cell. Mol. Biol. 2004, 30:627-634.
2. Arnold H., Bumann D., Felies M., Gewecke B., Soerensen M., Gessner J.E., Freihorst J., von Specht B.U., Baumann U. Enhanced immunogenicity in the murine airway mucosa with an attenuated Salmonella live vaccine expressing OprF-OprI from Pseudomonas aeruginosa. Infect. Immun. 2004, 72:6546-6553.
3. Baumann U., Mansouri E., von Specht B.U. Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections. Vaccine 2004, 22:840-847.
4. Baumann U., Stocklassa C., Greiner W., Graf von der Schulenburg J.-M., von der Hardt H. Costs of care and clinical conditions in paediatric cystic fibrosis patients. J. Cyst. Fibros. 2003, 2:84-90.
5. Baumann U., Göcke K., Gewecke B., Freihorst J., von Specht B.U. Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I/II study. Respir. Res. 2007, 5:57.
6. Boyce J.M. Antiseptic technology: access, affordability, and acceptance. Emerg. Infect. Dis. 2001, 7:231-233.
7. Botzenhart K., Döring G. Epidemiology and ecology of Pseudomonas aeruginosa. Pseudomonas aeruginosa as an Opportunistic Pathogen 1993, 1-18. New York, Plenum. M. Campa, M. Bendinelli, H. Friedman (Eds.).
8. Cheng K., Smyth R.L., Govan J.R., Doherty C., Winstanley C., Denning N., Heaf D.P., van Saene H., Hart C.A. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 1996, 348:639-642.
9. Cryz S.J. Pseudomonas aeruginosa vaccines. Vaccines and Immunotherapy 1991, 156-165. Pergamon Press, New York. S.J. Cryz (Ed.).
10. Cryz S.J., Sadoff J.C., Cross A.S., Fürer E. Safety and immunogenicity of a polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A vaccine in humans. Antibiot. Chemother. 1989, 42:177-183.
11. Cryz S.J., Fürer E., Que J.U. Synthesis and characterization of a Pseudomonas aeruginosa alginate-toxin A conjugate vaccine. Infect. Immun. 1991, 59:45-50.
12. Cryz S.J., Wedgwood J., Lang A.B., Ruedeberg A., Que J.U., Fürer E., Schaad U.B. Immunization of noncolonized cystic fibrosis patients against Pseudomonas aeruginosa. J. Infect. Dis. 1994, 169:1159-1162.
13. Cystic Fibrosis Foundation, 2008. Patient Registry, 2007. Annual Data Report. Cystic Fibrosis Foundation, Bethesda, MD, USA.
14. Cystic Fibrosis Genetic Analysis Consortium. http:/www.genet.sickkids.on.ca/cftr/.
15. DiGiandomenico A., Rao J., Goldberg J.B. Oral vaccination of BALB/c mice with Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model. Infect. Immun. 2004, 72:7012-7021.
16. DiGiandomenico A., Rao J., Harcher K., Zaidi T.S., Gardner J., Neely A.N., Pier G.B., Goldberg J.B. Intranasal immunization with heterologously expressed polysaccharide protects against multiple Pseudomonas aeruginosa infections. Proc Natl. Acad. Sci. USA 2007, 104:4624-4629.
17. Döring G., Ulrich M., Müller W., Bitter J., Schmidt-Koenig L., Münst L., Grupp H., Wolz C., Stern M., Botzenhart K. Generation of Pseudomonas aeruginosa aerosols during hand washing from contaminated sink drains, transmission to hands of hospital personnel, and its prevention by use of a new heating device. Zbl. Hyg. 1991, 191:494-505.
18. Döring G., Pfeiffer C., Weber U., Mohr-Pennert A., Dorner F. Parenteral application of a Pseudomonas aeruginosa flagella vaccine elicits specific anti-flagella antibodies in the airways of healthy individuals. Am. J. Respir. Crit. Care Med. 1995, 151:983-985.
19. Döring G., Jansen S., Noll J., Grupp H., Frank F., Botzenhart K., Magdorf K., Wahn U. Distribution and transmission of Pseudomonas aeruginosa and Burkholderia cepacia in a hospital ward. Pediatr. Pulmonol. 1996, 21:90-100.
20. Döring G., Conway S.P., Heijerman H.G.M., Hodson M.E., Høiby N., Smyth A., Touw D.J., for the Consensus Committee Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur. Respir. J. 2000, 16:749-767.
21. Döring G., Høiby N., for the Consensus Study Group Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J. Cyst. Fibros. 2004, 3:67-91.
22. Döring G., Ratjen F. Immunology of cystic fibrosis. Cystic Fibrosis 2007, 69-80. Arnold Hammer, London. M.E. Hodson, D. Geddes, A. Bush (Eds.).
23. Döring G., Meisner C., Stern M. A double-blind, randomized, placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:11020-11025.
24. Döring G., Pier G.B. Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine 2008, 26:1011-1024.
25. Döring G., Gulbins E. Cystic fibrosis and innate immunity: how chloride channel mutations provoke lung disease. Cell. Microbiol. 2009, 11:208-216.
26. Driscoll J.A., Brody S.L., Kollef M.H. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 2007, 67:351-368.
27. Duchene M., Barron C., Schweizer A., von Specht B.U., Domdey H. Pseudomonas aeruginosa outer membrane lipoprotein I gene: molecular cloning sequence, and expression in Escherichia coli. J. Bacteriol. 1989, 171:4130-4137.
28. Farrell P.M., Rosenstein B.J., White T.B., Accurso F.J., Castellani C., Cutting G.R., Durie P.R., Legrys V.A., Massie J., Parad R.B., Rock M.J., Campbell P.W. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: cystic fibrosis foundation consensus report. J. Pediatr. 2008, 153:S4-S14.
29. Feldman M., Bryan R., Rajan S., Scheffler L., Brunnert S., Tang H., Prince A. Role of flagella in pathogenesis of Pseudomonas aeruginosa pulmonary infection. Infect. Immun. 1998, 66:43-51.
30. Feuillet V., Medjane S., Mondor I., Demaria O., Pagni P.P., Galan J.E., Flavell R.A., Alexopoulou L. Involvement of toll-like receptor 5 in the recognition of flagellated bacteria. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:12487-12492.
31. Frederiksen B., Koch C., Høiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr. Pulmonol. 1997, 23:330-335.
32. Frederiksen B., Koch C., Høiby N. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995). Pediatr. Pulmonol. 1999, 8:59-66.
33. Geller D.E. Aerosol antibiotics in cystic fibrosis. Respir. Care 2009, 54:658-670.
34. Gibson R.L., Emerson J., McNamara S., Burns J.L., Rosenfeld M., Yunker A., Hamblett N., Accurso F., Dovey M., Hiatt P., Konstan M.W., Moss R., Retsch-Bogart G., Wagener J., Waltz D., Wilmott R., Zeitlin P.L., Ramsey B., Cystic Fibrosis Therapeutics Development Network Study Group Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2003, 167:819-841.
35. Gilleland H.E., Gilleland L.B., Fowler M.R. Vaccine efficacies of elastase, exotoxin A and outer-membrane protein F in preventing chronic pulmonary infection by Pseudomonas aeruginosa in a rat model. J. Med. Microbiol. 1993, 38:79-86.
36. Heijerman H., Westerman E., Conway S., Touw D., Döring G., for the consensus working group Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus. J. Cyst. Fibros. 2009, 8:295-315.
37. Høiby N., Pedersen S.S. Estimated risk of cross-infection with Pseudomonas aeruginosa in Danish cystic fibrosis patients. Acta Paediatr. Scand. 1989, 78:395-404.
38. Holder I.A., Naglich J.G. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: immunization using divalent flagella preparations. J. Trauma 1986, 26:118-122.
39. Holder I.A., Neely A.N., Frank D.W. PcrV immunization enhances survival of burned Pseudomonas aeruginosa-infected mice. Infect. Immun. 2001, 69:5908-5910.
40. Holder I.A. Pseudomonas immunotherapy: a historical overview. Vaccine 2004, 22:831-839.
41. Hollyoak V., Allison D., Summers J. Pseudomonas aeruginosa wound infection associated with a nursing home's whirlpool bath. Commun. Dis. Rep. CDR Rev. 1995, 5:R100-R102.
42. Jang I.J., Kim I.S., Park W.J., Yoo K.S., Yim D.S., Kim H.K., Shin S.G., Chang W.H., Lee N.G., Jung S.B., Ahn D.H., Cho Y.J., Ahn B.Y., Lee Y., Kim Y.G., Nam S.W., Kim H.S. Human immune response to a Pseudomonas aeruginosa outer membrane protein vaccine. Vaccine 1999, 17:158-168.
43. Jensen E.T., Giwercman B., Ojeniyi B., Bangsborg J.M., Hansen A., Koch C., Fiehn N.E., Høiby N. Epidemiology of Pseudomonas aeruginosa in cystic fibrosis and the possible role of contamination by dental equipment. J. Hosp. Infect. 1997, 36:117-122.
44. Jones A.M., Webb A.K., Govan J.R., Hart C.A., Walshaw M.J. Pseudomonas aeruginosa cross-infection in cystic fibrosis. Lancet 2002, 359:527-528.
45. Kashef N., Behzadian-Nejad Q., Najar-Peerayeh S., Mousavi-Hosseini K., Moazzeni M., Djavid G.E. Synthesis and characterization of Pseudomonas aeruginosa alginate-tetanus toxoid conjugate. J. Med. Microbiol. 2006, 55:1441-1446.
46. Kim D.K., Kim J.J., Kim J.H., Woo Y.M., Kim S., Yoon D.W., Choi C.S., Kim I., Park W.J., Lee N., Jung S.B., Ahn B.Y., Nam S.W., Yoon S.M., Choi W.J. Comparison of two immunization schedules for a Pseudomonas aeruginosa outer membrane proteins vaccine in burn patients. Vaccine 2000, 19:1274-1283.
47. Knapp B., Hundt E., Lenz U., Hungerer K.D., Gabelsberger J., Domdey H., Mansouri E., Li Y., von Specht B.U. A recombinant hybrid outer membrane protein for vaccination against Pseudomonas aeruginosa. Vaccine 1999, 17:1663-1666.
48. Lang A.B., Rüdeberg A., Schöni M.H., Que J.U., Fürer E., Schaad U.B. Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. Pediat. Infect. Dis. J. 2004, 23:504-510.
49. Larbig M., Mansouri E., Freihorst J., Tümmler B., Kohler G., Domdey H., Knapp B., Hungerer K.D., Hundt E., Gabelsberger J., von Specht B.U. Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Vaccine 2001, 19:2291-2297.
50. Lechtzin N., John M., Irizarry R., Merlo C., Diette G.B., Boyle M.P. Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration 2006, 73:27-33.
51. Littlewood J.M., Miller M.G., Ghoneim A.T., Ramsden C.H. Nebulised colomycin for early Pseudomonas aeruginosa colonisation in cystic fibrosis. Lancet 1985, 1:865.
52. Malfroot A., Adam G., Ciofu O., Döring G., Knoop C., Lang A.B., Van Damme P., Dab I., Bush A., for the European Cystic Fibrosis Society (ECFS) Vaccination Group Immunisation in the current management of cystic fibrosis patients. J. Cyst. Fibros. 2005, 4:77-87.
53. Mansouri E., Gabelsberger J., Knapp B., Hundt E., Lenz U., Hungerer K.D., Gilleland H.E., Staczek J., Domdey H., von Specht B.U. Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Infect. Immun. 1999, 67:1461-1470.
54. Mansouri E., Blome-Eberwein S., Gabelsberger J., Germann G., von Specht B.U. Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients. FEMS Immunol. Med. Microbiol. 2003, 37:161-166.
55. Munck A., Bonacorsi S., Mariani-Kurkdjian P., Lebourgeois M., Gerardin M., Brahimi N., Navarro J., Bingen E. Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization. Pediatr. Pulmonol. 2001, 32:288-292.
56. Mutharia L.M., Nicas T.L., Hancock R.E.W. Outer membrane proteins of P. aeruginosa serotype strains. J. Infect. Dis. 1982, 146:770-779.
57. Ohama M., Hiramatsu K., Miyajima Y., Kishi K., Nasu M., Kadota J. Intratracheal immunization with pili protein protects against mortality associated with Pseudomonas aeruginosa pneumonia in mice. FEMS Immunol. Med. Microbiol. 2006, 47:107-115.
58. Park W.J., Kim Y.H., Jeong S.M., Park K.H., Kim H.S., Kim Y.S., Hahm K.S., Munt P.L., Algate D.R. General pharmacology of a Pseudomonas vaccine prepared from outer-membrane fractions of Pseudomonas aeruginosa. Arzneimittelforschung 1996, 46:1001-1006.
59. Pier G.B. Promises and pitfalls of Pseudomonas aeruginosa lipopolysaccharide as a vaccine antigen. Carbohyd. Res. 2003, 338:2549-2556.
60. Priebe G.P., Brinig M.M., Hatano K., Grout M., Coleman F.T., Pier G.B., Goldberg J.B. Construction and characterization of a live, attenuated aroA deletion mutant of Pseudomonas aeruginosa as a candidate intranasal vaccine. Infect. Immun. 2002, 70:1507-1517.
61. Priebe G.P., Meluleni G.J., Coleman F.T., Goldberg J.B., Pier G.B. Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant. Infect. Immun. 2003, 71:1453-1461.
62. Price B.M., Liner A.L., Park S., Leppla S.H., Mateczun A., Galloway D.R. Protection against Pseudomonas aeruginosa chronic lung infection in mice by genetic immunization against outer membrane protein F (OprF) of P. aeruginosa. Infect. Immun. 2001, 69:3510-3515.
63. Prince A. Flagellar activation of epithelial signaling. Am. J. Respir. Cell Mol. Biol. 2006, 34:548-551.
64. Ramphal R., Guay C., Pier G.B. Pseudomonas aeruginosa adhesins for tracheobronchial mucin. Infect. Immun. 1987, 55:600-603.
65. Ramsey D.M., Wozniak D.J. Understanding the control of Pseudomonas aeruginosa alginate synthesis and the prospects for management of chronic infections in cystic fibrosis. Mol. Microbiol. 2005, 56:309-322.
66. Ratjen F., Döring G., Nikolaizik W.H. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 2001, 358:983-984.
67. Ratjen F., Walter H., Haug M., Meisner C., Grasemann H., Döring G. Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients. Pediatr. Pulmonol. 2007, 42:249-255.
68. Rudner X.L., Hazlett L.D., Berk R.S. Systemic and topical protection studies using Pseudomonas aeruginosa flagella in an ocular model of infection. Curr. Eye Res. 1992, 11:727-738.
69. Saiman L., Siegel J. Infection control in cystic fibrosis. Clin. Microbiol. Rev. 2004, 17:57-71.
70. Salunkhe P., Smart C.H., Morgan J.A., Panagea S., Walshaw M.J., Hart C.A., Geffers R., Tümmler B., Winstanley C. A cystic fibrosis epidemic strain of Pseudomonas aeruginosa displays enhanced virulence and antimicrobial resistance. J. Bacteriol. 2005, 187:4908-4920.
71. Sawa T., Yahr T.L., Ohara M., Kurahashi K., Gropper M.A., Wiener-Kronish J.P., Frank D.W. Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nature Med. 1999, 5:392-398.
72. Schaad U.B., Lang A.B., Wedgwood J., Ruedeberg A., Que J.U., Fürer E., Cryz S.J. Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis. Lancet 1991, 338:1236-1237.
73. Sedlak-Weinstein E., Cripps A.W., Kyd J.M., Foxwell A.R. Pseudomonas aeruginosa: the potential to immunise against infection. Exp. Opin. Biol. Ther. 2005, 5:967-982.
74. Sheth H.B., Glasier L.M., Ellert N.W., Cachia P., Kohn W., Lee K.K., Paranchych W., Hodges R.S., Irvin R.T. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein. Biomed. Pept. Proteins Nucleic Acids 1995, 1:141-148.
75. Skjak-Braek G., Grasdalen H., Larsen B. Monomer sequence and acetylation pattern in some bacterial alginates. Carbohydr. Res. 1986, 154:239-250.
76. Staczek J., Gilleland L.B., van der Heyde H.C., Gilleland H.E. DNA vaccines against chronic lung infections by Pseudomonas aeruginosa. FEMS Immunol. Med. Microbiol. 2003, 37:147-153.
77. Taccetti G., Repetto T., Procopio E., Farina S., Campana S. Early Pseudomonas aeruginosa colonization in cystic fibrosis patients. Lancet 2002, 359:625-626.
78. Taccetti G., Campana S., Festini F., Mascherini M., Döring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur. Respir. J. 2005, 26:1-4.
79. Theilacker C., Coleman F.T., Mueschenborn S., Llosa N., Grout M., Pier G.B. Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine. Infect. Immun. 2003, 71:3875-3884.
80. Umelo-Njaka E., Nomellini J.F., Bingle W.H., Glasier L.G.M., Irvin R.T., Smit J. Expression and testing of Pseudomonas aeruginosa vaccine candidate proteins prepared with the Caulobacter crescentus S-layer protein expression system. Vaccine 2001, 19:1406-1415.
81. Valerius N.H., Koch C., Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation by early treatment. Lancet 1991, 338:725-726.
82. von Specht B.U., Knapp B., Muth G., Bröker M., Hungerer K.D., Diehl K.D., Massarrat K., Seemann A., Domdey H. Protection of immunocompromised mice against lethal infection with P. aeruginosa by active or passive immunization with recombinant P. aeruginosa outer membrane protein F and outer membrane protein I fusion proteins. Infect. Immun. 1995, 63:1855-1861.
83. von Specht B.U., Lücking H.C., Blum B., Schmitt A., Hungerer K.D., Domdey H. The Pseudomonas aeruginosa outer membrane protein I vaccine: immunogenicity and safe administration in man. Behring Inst. Mitteil. 1997, 98:326-337.
84. Wiesemann H.G., Steinkamp G., Ratjen F., Bauernfeind A., Przyklenk B., Döring G., von der Hardt H. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr. Pulmonol. 1998, 25:88-92.
85. Zuercher A.W., Horn M.P., Wu H., Song Z., Bundgaard C.J., Johansen H.K., Høiby N., Marcus P., Lang A.B. Intranasal immunisation with conjugate vaccine protects mice from systemic and respiratory tract infection with Pseudomonas aeruginosa. Vaccine 2006, 24:4333-4342.
86. Zuercher A.W., Horn M.P., Que J.U., Ruedeberg A., Schoeni M.H., Schaad U.B., Marcus P., Lang A.B. Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis. FEMS Immunol. Med. Microbiol. 2006, 47:302-308.
87. Zuercher A.W., Imboden M.A., Jampen S., Bosse D., Ulrich M., Chtioui H., Lauterburg B.H., Lang A.B. Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine. Clin. Exp. Immunol. 2006, 143:132-138.